Filana Therapeutics, Inc.
Moat Score — Filana Therapeutics, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Filana holds an exclusive worldwide license from Yale covering intellectual property for simufilam's use in tuberous sclerosis complex-related epilepsy, giving it a real legal claim on this specific application of its filamin A mechanism, though the underlying science remains clinically unproven and the broader simufilam Alzheimer's patent estate lost most of its value when that program failed Phase 3. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue, 20-person clinical-stage biotech reliant entirely on outsourced preclinical and clinical work, Filana has no manufacturing or operating cost advantage over any other small drug developer; its 2025 cost base was dominated by legacy legal and settlement expenses rather than efficient operations. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Filana has no approved product and therefore no current pricing power; if simufilam were eventually approved for TSC-related epilepsy, a rare-disease indication could support premium orphan-drug-like pricing similar to Afinitor Disperz, but this is entirely speculative given the drug has not cleared even an initial proof-of-concept trial. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in Filana's business; it is a single-molecule drug developer where value does not compound as more patients, physicians, or partners are added to any platform or ecosystem. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no approved or marketed product, there is no prescriber or patient base to generate switching costs; any future switching costs would depend entirely on simufilam first demonstrating efficacy and gaining approval in TSC-related epilepsy. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Tuberous sclerosis complex-related epilepsy is a narrow, rare-disease population where only one disease-specific drug (everolimus) is currently approved, suggesting the addressable market may be too small to draw many new entrants if simufilam eventually succeeds, but Filana has not yet proven clinical efficacy or cleared its FDA clinical hold, so this advantage remains hypothetical. |